Suppr超能文献

多中心回顾性队列研究卵巢生殖细胞肿瘤:化疗降级的证据和儿科与成人实践的一致。

A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice.

机构信息

Barts Health NHS Trust, West Smithfield, London, EC1A 7BE, UK; University College Hospital, 235 Euston Road London, NW1 2BU, UK; University Hospitals Bristol NHS Foundation Trust, Upper Maudlin Street, Bristol, BS2 8HW, UK; University of Bristol, Senate House, Tyndall Avenue, Bristol BS8 1TH, UK.

The Royal Marsden Hospital, 203 Fulham Rd, Chelsea, London SW3 6JJ, UK.

出版信息

Eur J Cancer. 2019 May;113:19-27. doi: 10.1016/j.ejca.2019.03.001. Epub 2019 Apr 4.

Abstract

BACKGROUND

Adult guidelines recommend BEP (bleomycin, etoposide, cisplatin) for all ovarian germ cell tumours, causing debilitating toxicities in young patients who will survive long term. Paediatricians successfully reduce toxicities by using lower bleomycin doses and substituting carboplatin for cisplatin, while testicular and paediatric immature teratomas (ITs) are safely managed with surgery alone.

AIM

The aim was to determine whether reduced-toxicity treatment could rationally be extended to patients older than 18 years.

METHODS

Multicentre cohort study was carried out in four large UK cancer centres over 12 years.

RESULTS

One hundred thirty-eight patients were enrolled. Overall survival was 93%, and event-free survival (EFS) was 72%. Neoadjuvant/adjuvant chemotherapy (82% BEP) caused 27 potentially chronic toxicities, and one patient subsequently died from acute lymphoblastic leukaemia. There was no difference in histology, stage or grade in patients ≤/>18 years, and EFS was not different in these age groups (≤18:28% and >18:28%; log-rank P = 0.96). Histological subtype powerfully predicted EFS (log-rank P = 4.9 × 10). Neoadjuvant/adjuvant chemotherapy reduced future relapse/progression in dysgerminoma (n = 37, chemo:0% vs. no chemo:20%), yolk sac tumour (n = 23, 26.3% vs.75%) and mixed germ cell tumour (n = 32, 40%vs.70%) but not in IT (n = 42, 33% vs.15%). Additionally, we observed no radiological responses to chemotherapy in ITs, pathological IT grade did not predict EFS (univariate hazard ratio 0.82, 95% confidence interval: 0.57-1.19, P = 0.94) and there were no deaths in this subtype.

CONCLUSION

Survival was excellent but chemotherapy toxicities were severe, implying significant overtreatment. Our data support the extension of reduced-toxicity, paediatric regimens to adults. Our practice-changing findings that IT was chemotherapy resistant and pathological grade uninformative strongly endorse exclusive surgical management of ovarian ITs at all ages.

摘要

背景

成人指南建议所有卵巢生殖细胞肿瘤患者使用 BEP(博来霉素、依托泊苷、顺铂)治疗,但这会导致年轻患者出现长期衰弱的毒性反应。儿科医生通过使用较低剂量的博来霉素和用卡铂替代顺铂,成功降低了毒性,而睾丸和儿科未成熟畸胎瘤(IT)仅通过手术即可安全治疗。

目的

目的是确定是否可以合理地将低毒性治疗扩展到 18 岁以上的患者。

方法

在 12 年间,在英国的四个大型癌症中心进行了多中心队列研究。

结果

共纳入 138 例患者。总生存率为 93%,无事件生存率(EFS)为 72%。新辅助/辅助化疗(82%为 BEP)导致 27 种潜在的慢性毒性,其中 1 例患者随后死于急性淋巴细胞白血病。≤18 岁和>18 岁患者的组织学、分期或分级无差异,且这些年龄组的 EFS 无差异(≤18 岁:28%和>18 岁:28%;对数秩检验 P=0.96)。组织学亚型强烈预测 EFS(对数秩检验 P=4.9×10)。新辅助/辅助化疗降低了畸胎瘤(n=37,化疗:0% vs. 无化疗:20%)、卵黄囊瘤(n=23,26.3% vs. 75%)和混合生殖细胞瘤(n=32,40% vs. 70%)的未来复发/进展风险,但 IT 无作用(n=42,33% vs. 15%)。此外,我们观察到 IT 对化疗无放射学反应,病理 IT 分级不能预测 EFS(单因素风险比 0.82,95%置信区间:0.57-1.19,P=0.94),且该亚型无死亡病例。

结论

生存情况良好,但化疗毒性严重,表明存在过度治疗。我们的数据支持将低毒性、儿科方案扩展到成人。我们的研究结果具有改变实践的意义,即 IT 对化疗有耐药性,且病理分级无信息提示,强烈支持在所有年龄段均仅采用手术治疗卵巢 IT。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b760/6522056/2b38c62818b4/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验